Medpace Holdings, Inc. $MEDP Stock Holdings Decreased by Coldstream Capital Management Inc.

Coldstream Capital Management Inc. lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,440 shares of the company’s stock after selling 113 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Medpace were worth $452,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Geneos Wealth Management Inc. raised its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Brooklyn Investment Group boosted its position in shares of Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after buying an additional 71 shares during the period. IFP Advisors Inc grew its holdings in shares of Medpace by 223.3% during the second quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after buying an additional 134 shares in the last quarter. Hantz Financial Services Inc. raised its position in Medpace by 5,075.0% during the second quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock valued at $65,000 after buying an additional 203 shares during the period. Finally, Assetmark Inc. lifted its stake in Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company’s stock worth $66,000 after acquiring an additional 43 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on MEDP shares. Jefferies Financial Group lifted their target price on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Robert W. Baird set a $613.00 price objective on shares of Medpace in a research report on Friday, October 24th. Truist Financial set a $555.00 target price on shares of Medpace in a research report on Monday, October 27th. Finally, Rothschild & Co Redburn lowered shares of Medpace from a “buy” rating to a “neutral” rating and lifted their target price for the company from $342.00 to $474.00 in a research note on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $487.18.

Medpace Stock Performance

NASDAQ:MEDP opened at $606.60 on Friday. The company has a market capitalization of $17.09 billion, a P/E ratio of 42.42, a P/E/G ratio of 2.67 and a beta of 1.42. The stock’s 50 day moving average price is $558.59 and its 200 day moving average price is $441.45. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $626.26.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, President Jesse J. Geiger sold 21,503 shares of the stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the transaction, the president owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This represents a 58.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Stephen P. Ewald sold 15,230 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $598.85, for a total value of $9,120,485.50. Following the completion of the transaction, the general counsel directly owned 13,343 shares in the company, valued at $7,990,455.55. The trade was a 53.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 310,767 shares of company stock valued at $185,879,561. Corporate insiders own 20.30% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.